A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur

Supplemental Data for the Juvenile Idiopathic Arthritis FDA Written Request

This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept

Inclusion Criteria:

• Two diagnoses of JIA (ICD-9 code 714.3x) within 90 days
• Age less than 18 years at the time of second of the two diagnoses
• Index date is the date of initiating treatment with abatacept

Exclusion Criteria:

• Greater than or equal to 18 years of age